A Longitudinal Study Of Natural Killer Cell Function In HIV-infected Individuals Initiating Therapy
Funder
National Health and Medical Research Council
Funding Amount
$620,176.00
Summary
HIV infected people no longer die from AIDS but suffer and die from non-AIDS conditions such as non-AIDS related cancers. We have discovered persistent abnormalities in natural killer cells in HIV patients receiving antiretroviral therapy. These cells help prevent the development of and control cancers so understanding why they are abnormal in HIV patients will help prevent early death from non-AIDS cancers.
HIV is a rapidly evolving virus, and within an infected individual it continually acquires new mutations and joins together mutations by recombination. We have developed a novel system for studying recombination, and find that different individuals have different recombination rates, which may contribute to why some individuals survive longer. This project aims to identify the mechanisms responsible for differing recombination rates and how we can alter these to improve patient outcome.
Signals And Noise: A Study Of The Neurocognitive Mechanisms Underpinning Habituation To Noise In Normal And Damaged Hearing
Funder
National Health and Medical Research Council
Funding Amount
$408,938.00
Summary
McLachlan and Wilson recently published the first model of hearing that combines brain structure with function. This model postulates that recognition mechanisms initiate first, and then regulate the processing of other features. This project will investigate whether recognition mechanisms enable the auditory system to adapt to repetitive (background) noise by predicting and inhibiting responses to these sounds, and any changes in these mechanisms that may accompany hearing damage and tinnitus.
Prevention Of HIV-1 Infection By Adeno Associated Virus Vector-delivered Broadly Neutralizing Antibodies Or Antibody-like Molecules
Funder
National Health and Medical Research Council
Funding Amount
$875,854.00
Summary
A promising neutralizing molecule has boosted hopes of an HIV vaccine. It remains unknown how well this molecule prevents HIV infection under conditions reflecting “real world” exposure, including exposure to HIV in the form of cells carrying virus or free-floating virus in the presence of semen. We will assess this molecule for their ability to inhibit transmission of HIV-like viruses under these conditions. These experiments will define requirements to protect against HIV infection.
Randomised Trial To Determine The Safety And Efficacy Of Early Vs Deferred Treatment Of HIV
Funder
National Health and Medical Research Council
Funding Amount
$1,070,331.00
Summary
Treatments for HIV represent a miraculous achievement of medical research. Global use of antiretroviral drugs has prevented substantial morbidity and mortality. However, it is unclear if these drugs should be used in people who are HIV positive with early HIV disease but no clinical symptoms. The START trial will result in a precise estimate of the risk-benefit for earlier versus later use of these treatments. It will immediately affect treatment guidelines around the world and inform future res ....Treatments for HIV represent a miraculous achievement of medical research. Global use of antiretroviral drugs has prevented substantial morbidity and mortality. However, it is unclear if these drugs should be used in people who are HIV positive with early HIV disease but no clinical symptoms. The START trial will result in a precise estimate of the risk-benefit for earlier versus later use of these treatments. It will immediately affect treatment guidelines around the world and inform future research for many years to come.Read moreRead less
Control Of Combined Simian-human Immunodeficiency Virus Infection Utilising NK Cells Mediating Antigen-specific Antibody Dependent Cellular Cytotoxicity - A Novel Vaccine Modality
Funder
National Health and Medical Research Council
Funding Amount
$432,587.00
Summary
Recently, progress was made in developing a vaccine against HIV. Our laboratory was selected to join a global collaboration trying to elucidate the key to this success. Attention has focused on non-neutralizing antibodies and our laboratory has developed a unique expertise in detecting such immune responses. This research will define, purify and manufacture these antibodies and test their ability to prevent HIV in animals with the ultimate aim of producing a vaccine for human use.
Monogamy As An HIV And STI Prevention Strategy For Gay Men
Funder
National Health and Medical Research Council
Funding Amount
$407,506.00
Summary
Monogamy is relatively common among Australian gay men and yet relatively under researched or explored. At present we know little about the motivations of Australian gay men to enter and maintain monogamous relationships. This study will bring into clear view a phenomenon, and social and intimate practice, that has been almost entirely overlooked and will significantly advance our understanding of the dynamics of gay men's sexual behaviour and sexual cultures.
Cochlear Type II Neurons In Contralateral Suppression
Funder
National Health and Medical Research Council
Funding Amount
$459,434.00
Summary
Sound in one ear affects hearing in the other ear. This contralateral suppression is important for hearing attention and protection from noise damage. We will test the hypothesis that cochlear type II sensory neurons provide the sensory input for this process using models where neuronal development is altered, or the neurons are removed. The study addresses hearing disability in society, facilitating cochlear prosthesis development and the understanding of hearing loss.
Studies On The Activation And Immunogenicity Of The HIV-1 Glycoproteins, Gp120-gp41
Funder
National Health and Medical Research Council
Funding Amount
$606,438.00
Summary
More than 34 million people were living with HIV-1 in 2011 with ~7,000 new infections still occurring daily. A prophylactic vaccine for HIV-1 is needed to stop its transmission, however, this goal is yet to be achieved. Our proposed studies will inform the design of prophylactic HIV-1 vaccines that act by making antibodies that neutralize the virus.
Successful HIV remission and cure, where patients can live normally without daily drug therapy and risk of transmitting infectious virus, will critically depend on understanding the mechanisms that control the expression of viral messenger RNA and proteins. This project further explores the mechanisms controling poorly understood steps in the proecssing of viral mRNA that are required for HIV protein produciton, and identifies new targets and strategies to drive HIV into permanent remission.